Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: February 26, 2009
Last updated: September 17, 2009
Last verified: July 2009

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of breast cancer. It is not yet known whether giving docetaxel together with a phytochemical is more effective than giving docetaxel alone in treating patients with breast cancer.

PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with a phytochemical works compared with giving docetaxel alone as first- or second-line therapy in treating patients with breast cancer.

Condition Intervention Phase
Breast Cancer
Dietary Supplement: phytochemical
Drug: docetaxel
Procedure: complementary or alternative medicine procedure
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate as assessed by RECIST criteria [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall clinical benefit rate as assessed by RECIST criteria [ Designated as safety issue: No ]
  • Time to progression as assessed by RECIST criteria [ Designated as safety issue: No ]
  • Overall survival as assessed by RECIST criteria [ Designated as safety issue: No ]
  • Safety as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: August 2009
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Detailed Description:



  • To compare the response rate in HER2-negative patients with locally advanced or metastatic breast cancer or locoregional breast cancer recurrence treated with docetaxel and a dietary phytochemical vs docetaxel alone.


  • To compare the overall clinical benefit rate (i.e., objective response plus stable disease) in patients treated with these regimens.
  • To compare time to progression in patients treated with these regimens.
  • To compare overall survival of patients treated with these regimens.
  • To assess biomarkers of response in blood samples from patients treated with these regimens.

OUTLINE: This is a multicenter study. Patients are stratified according to recruitment center and line of chemotherapy (first vs second line of docetaxel). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive docetaxel as in arm I. Patients also receive an oral dietary phytochemical twice on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the breast, meeting 1 of the following criteria:

    • Locally advanced disease
    • Documented metastatic disease without overexpression of Her2/neu

      • Must have received prior anthracycline-containing regimen as neoadjuvant, adjuvant, or first-line chemotherapy for metastatic breast cancer
    • Loco-regional recurrence not amenable to treatment by surgery or radiotherapy
  • At least one measurable lesion according to RECIST criteria

    • No bone lesion only disease
  • Must be a candidate for taxane-based chemotherapy
  • HER2-negative disease
  • No symptomatic brain metastases
  • Hormone receptor status not specified


  • Menopausal status not specified
  • WHO performance status 0-2
  • Life expectancy ≥ 3 months
  • ANC ≥ 2,000/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 10 g/dL
  • Serum creatinine < 140 µmol/L OR creatinine clearance > 60 mL/min
  • Total bilirubin ≤ upper limit of normal (ULN)
  • AST and ALT ≤ 1.5 times ULN
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No history of significant neurologic (i.e., peripheral neuropathy ≥ grade 2) or psychiatric disorders, including psychotic disorders, dementia, or seizures that would prohibit the understanding, observance, and giving of informed consent
  • No other prior or concomitant malignancies except adequately treated carcinoma in situ of the cervix uteri, basal cell or squamous cell carcinoma of the skin, or other cancer curatively treated with surgery and/or radiotherapy
  • No concurrent severe and/or uncontrolled co-morbid medical condition
  • No medically unstable patients
  • No uncontrolled infection
  • No autoimmune disease and/or chronic active inflammation
  • No psychological, familial, social, or geographical reasons that would make clinical follow-up impossible
  • No malabsorption syndrome or disease significantly affecting gastrointestinal function
  • No dysphagia ≥ grade 2
  • No history of hypersensitivity to taxanes or known excipients, including polysorbate 80


  • See Disease Characteristics
  • No prior major resection of the stomach or proximal small bowel
  • Prior hormonal therapy as adjuvant treatment and/or treatment of metastatic disease allowed provided that the patient has progressive disease at study entry

    • Hormonal treatment must be discontinued prior to study entry
  • No more than 1 prior chemotherapy regimen for metastatic disease
  • More than 30 days since prior investigational drug
  • More than 3 weeks since prior NSAIDs or COX_2 inhibitors
  • No other concurrent anticancer therapy
  • No other concurrent dietary phytonutrients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852332

Centre Jean Perrin Recruiting
Clermont-Ferrand, France, 63011
Contact: Philippe Chollet, MD, PhD    33-4-7327-8198   
Sponsors and Collaborators
Centre Jean Perrin
Principal Investigator: Philippe Chollet, MD, PhD Centre Jean Perrin
  More Information Identifier: NCT00852332     History of Changes
Other Study ID Numbers: CDR0000635901  JEANP-CURRYTAX  INCA-RECF0908  EUDRACT-2008-003930-19 
Study First Received: February 26, 2009
Last Updated: September 17, 2009
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
male breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
recurrent breast cancer
stage IIIA breast cancer
HER2-negative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2016